ReviewInternational journal of molecular sciences2019
Mechanisms Underlying Bone Loss Associated with Gut Inflammation.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- One-year supplementation with Lactobacillus reuteri ATCC PTA 6475 counteracts a degradation of gut microbiota in older women with low bone mineral density.NPJ biofilms and microbiomes · 2022Trial
- The Gut-Bone Axis: A Systematic Review on the Potential Intervention Pathways for Bone Health.Life (Basel, Switzerland) · 2026Review
- Cross-talk of gut-bone-muscle: osteosarcopenia in experimental colitis models.Laboratory animal research · 2026Review
- Exploring osteosarcopenia from the gut microbiota perspective: mechanistic insights and therapeutic potentials based on the gut-muscle-bone Axis.Frontiers in microbiology · 2026Review
- Interaction between diabetes and osteoporosis: imbalance between inflammation and bone remodeling.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Review
- The Incidence of Osteoporosis in Hepatocellular Carcinoma Patients Under 65: A Retrospective Cohort Study.Cureus · 2025Article
- Article
- Modulation of the gut-bone axis:Frontiers in immunology · 2025Article
- Association between triglycerides and lumbar bone mineral density in Chinese patients with osteoporotic fractures: a retrospective cross-sectional study.Scientific reports · 2024Article
- Investigating the association between osteopenia and bowel perforation through a multicenter radiologic analysis.Scientific reports · 2024Article
- Article
- Article
- Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases.Cell reports. Medicine · 2023Article
- Gut microbiota and metabonomics used to explore the mechanism of Qing'e Pills in alleviating osteoporosis.Pharmaceutical biology · 2022Article
- Heat-KilledFrontiers in nutrition · 2022Article
- Gut microbiome depletion and repetitive mild traumatic brain injury differentially modify bone development in male and female adolescent rats.Bone reports · 2021Article
- Editorial: Special Issue on "Molecular Mechanisms Regulating Osteoclastogenesis".International journal of molecular sciences · 2020Article
- Denosumab Regulates Gut Microbiota Composition and Cytokines in Dinitrobenzene Sulfonic Acid (DNBS)-Experimental Colitis.Frontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Patients with gastrointestinal diseases frequently suffer from skeletal abnormality, characterized by reduced bone mineral density, increased fracture risk, and/or joint inflammation. This pathological process is characterized by altered immune cell activity and elevated inflammatory cytokines in the bone marrow microenvironment due to disrupted gut immune response. Gastrointestinal disease is recognized as an immune malfunction driven by multiple factors, including cytokines and signaling molecules. However, the mechanism by which intestinal inflammation magnified by gut-residing actors stimulates bone loss remains to be elucidated. In this article, we discuss the main risk factors potentially contributing to intestinal disease-associated bone loss, and summarize current animal models, illustrating gut-bone axis to bridge the gap between intestinal inflammation and skeletal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.